Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

被引：1
|
作者：
Day, D. [1 ,2 ]
Starus, A. [3 ]
Gebski, V. [4 ]
Simes, J. [4 ]
Hayes, T. [5 ]
Padinharakam, S. [6 ]
Strickland, A. H. [1 ,2 ]
Briscoe, K. [7 ]
Varma, S. [8 ]
Barnet, M. [9 ]
Jackson, C. [10 ]
Horvath, L. G. [11 ]
Price, T. J. [12 ,13 ]
Tebbutt, N. [14 ]
Karki, B. [15 ]
Diakos, C. I. [16 ]
Chia, J. [17 ]
Toh, H. C. [17 ]
Jones, F. S. [3 ]
Segelov, E. [18 ]
机构：
[1] Monash Hlth, Dept Oncol, Clayton, Vic, Australia
[2] Dept Med, Clayton, Vic, Australia
[3] Sysmex Inost Inc, Med Affairs, Baltimore, MD USA
[4] Univ Sydney, NHMRC Clin Trial Ctr, Sydney, NSW, Australia
[5] Southwest Oncol, Med Oncol, Warrnambool, Vic, Australia
[6] Launceston Gen Hosp, Specialist Care Australia, Launceston, NSW, Australia
[7] Mid North Coast Canc Inst, Med Oncol, Coffs Harbour, NSW, Australia
[8] Townsville Hosp, Dept Oncol, Douglas, Qld, Australia
[9] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[10] Dunedin Publ Hosp, Dept Med Oncol, Dunedin, New Zealand
[11] Chris OBrien Lifehouse, Med Oncol, Camperdown, NSW, Australia
[12] Univ Adelaide, Med Oncol, Adelaide, SA, Australia
[13] Lyell McEwin Hosp, Elizabeth Vale, SA, Australia
[14] Austin Hlth, Dept Oncol, Heidelberg, Vic, Australia
[15] Toowoomba Gen Hosp, Toowoomba Hosp Canc Ctr Serv, Clayton, Vic, Australia
[16] Genesis Care North Shore, Dept Med Oncol, St Leonards, NSW, Australia
[17] NCCS, Dept Med Oncol, Singapore, Singapore
[18] Univ Bern, Dept Clin Res, Fac Med, Bern, Switzerland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1777
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
586P
引用
收藏
页码：S426 / S427
页数：2
相关论文
共 50 条
  • [21] A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
    Srinivasan, G.
    Hubert, A.
    Purim, O.
    Semenisty, V.
    Lo, N.
    Tsukada, Y.
    Mondello, G.
    Cubillo, A.
    Subramaniam, S.
    Palomares, M. R.
    Baehner, R. F. L.
    De Jong, F.
    Kerr, D. J.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S69 - S70
  • [22] Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a UK multicenter prospective study (TRACC)
    Anandappa, Gayathri
    Starling, Naureen
    Begum, Ruwaida
    Bryant, Annette
    Sharma, Shruti
    Renner, Derrick
    Aresu, Maria
    Peckitt, Clare
    Sethi, Himanshu
    Feber, Andrew
    Potter, Vanessa Alice
    Paraoan, Marius
    Abulafi, Muti
    George, Nicol
    Branagan, Graham
    Duff, Sarah
    West, Nicholas
    Aleshin, Alexey
    Chau, Ian
    Cunningham, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
    Armstrong, A. J.
    Saad, F.
    Thiery-Vuillemin, A.
    Oya, M.
    Shore, N. D.
    Mehra, N.
    Ozguroglu, M.
    Gedye, C.
    Sartor, O.
    Poehlein, C. H.
    Qiu, P.
    Liu, Y-Z.
    Riva, L.
    Harrington, L.
    Barker, L.
    Del Rosario, P. M. D.
    Barnicle, A.
    Clarke, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1168 - S1168
  • [24] Multiomic, plasma-only circulating tumor DNA (ctDNA) assay identifies breast cancer patients with minimal residual disease (MRD) and predicts distant recurrence
    Janni, Wolfgang
    Huober, Jens
    Braun, Tatjana
    Mueller, Volkmar
    Fink, Angelina
    de Gregorio, Amelie
    Rack, Brigitte
    Friedl, Thomas W.
    Wiesmueller, Lisa
    Pantel, Klaus
    Rich, Thereasa
    Parsana, Princy
    Zotenko, Elena
    Zhang, Shile
    Huesmann, Sophia
    CANCER RESEARCH, 2022, 82 (12)
  • [25] A patient-specific, tumor-informed, circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) assay in surgical patients with biliary tract cancer
    Song, Tianqiang
    Wu, Qiang
    Cui, Yunlong
    Li, Huikai
    Zhang, Wei
    Fang, Feng
    Xiong, Qingqing
    CANCER RESEARCH, 2023, 83 (07)
  • [26] Patient-specific tumor-informed circulating tumor DNA (ctDNA) analysis for molecular residual disease (MRD) detection in surgical patients with stage I-IV colorectal cancer (CRC).
    Cao, Di
    Wang, Fu-Long
    Li, Cong
    Zhang, Rong-Xin
    Wu, Xiao-Jun
    Li, Liren
    Lu, Zhen-Hai
    Pan, Zhi-Zhong
    Lin, Jun-zhong
    Wu, Miaoqing
    Liu, Yifan
    Lv, Guangzhao
    Li, Min
    Wang, Chenyang
    Li, Xi
    Chen, Gong
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 213 - 213
  • [27] Analysis of ctDNA for the detection of minimal residual disease (MRD) using a tissue-free, multiomic assay in patients with early-stage breast cancer
    Janni, Wolfgang
    Friedl, Thomas
    Rack, Brigitte
    Fasching, Peter A.
    Hartkopf, Andreas
    Tesch, Hans
    Lorenz, Ralf
    Heinrich, Georg
    Blohmer, Jens-Uwe
    Fehm, Tanja
    Mueller, Volkmar
    Schneeweiss, Andreas
    Beckmann, Matthias
    Ruebner, Matthias
    Harbeck, Nadia
    Pantel, Klaus
    Dustin, Derek
    Cai, Mingyang
    CANCER RESEARCH, 2024, 84 (09)
  • [28] Comprehensive genomic analysis of molecular residual disease based on circulating tumour DNA in postoperative patients with colorectal cancer
    Hong, Qingqi
    Zhu, Jingtao
    Lin, Hexin
    Chen, Yinan
    Bai, Haoyu
    Yan, Linghua
    Xiao, Li
    You, Jun
    CLINICAL AND TRANSLATIONAL MEDICINE, 2024, 14 (10):
  • [29] Monitoring minimal residual disease (MRD) by KRAS mutation burden in urinary or plasma circulating tumor (ct) DNA in colorectal cancer (CRC) patients with resectable liver metastases
    Vibat, Cecile Rose T.
    Melnikova, Vlada
    Minarik, Marek
    Belsanova, Barbora
    Hancock, Saege
    Hassaine, Latifa
    Samuelsz, Errin
    Lu, Timothy T.
    Erlander, Mark G.
    Benesova, Lucie
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Circulating tumour DNA (ctDNA) as a prognostic biomarker in patients (pts) with refractory metastatic colorectal cancer (mCRC) receiving TAS102 with or without bevacizumab
    Saoudi Gonzalez, N.
    Navarro Garces, V.
    Salva Ballabrera, F.
    Ros Montana, F. J.
    Baraibar Argota, I.
    Rodriguez Castells, M.
    Vaghi, C.
    Garcia Rodriguez, A.
    Alcaraz, A.
    Comas, R.
    Dienstmann, R.
    Tabernero, J.
    Vivancos, A.
    Elez Fernandez, M. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S58 - S59
12345